Results 121 to 130 of about 39,781 (168)

Mucosal and systemic immune signatures reveal compartmentalized regulation of gut barrier integrity in virologically suppressed HIV Infection. [PDF]

Front Immunol
Artusa V, Zamarato R, De Luca L, Benedetti L, Compagno M, Cano Fiestas MA, Bottan D, Clerici M, Biasin M, Trabattoni D, MARISA Study Group.   +10 more
europepmc   +1 more source

Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom. [PDF]

AIDS
Foster C, Blenkinsop A, Henderson M, Lyall H, Fidler S, BONDY study group.   +5 more
europepmc   +1 more source

Non-integrase mechanisms for dolutegravir resistance. [PDF]

Retrovirology
Engelman AN.
europepmc   +1 more source

Comparative effectiveness and safety of integrase strand transfer inhibitor (INSTI)-based versus non-INSTI-based antiretroviral regimens in treatment-naïve people with HIV: A real-world retrospective cohort study. [PDF]

Medicine (Baltimore)
Ye X, Han J, Zhang Y, Yang C, Zuo Z, Huang L, Hu L, Lei J, Wang M, Cui H, Chen X.   +10 more
europepmc   +1 more source

A French national observatory of people with HIV initiating lenacapavir-based treatment after regulatory approval. [PDF]

Antimicrob Agents Chemother
Charpentier C, Montrouge T, Wirden M, Avettand-Fenoel V, Tumiotto C, Bellecave P, Rodallec A, Garnier E, Fofana D, Lambert-Niclot S, Montès B, Chaix M-L, Charre C, Gantner P, Bouvier-Alias M, Alidjinou EK, Coulon P, Mchantaf G, Beby-Defaux A, Alessandri-Gradt E, Moisan A, Le Hingrat Q, Lê M, Delaugerre C, Marcelin A-G, Peytavin G, Calvez V, Descamps D, Lenacapavir Observatory Study Group.   +28 more
europepmc   +1 more source

Temporal Evolution of Drug Resistance to HIV Integrase Inhibitors. [PDF]

Viruses
Choudhuri I, Olvera JG, Biswas A, Haldane A, Levy RM, Lyumkis D.   +5 more
europepmc   +1 more source

Combined injectable regimens in treatment-experienced HIV/AIDS patients at a southern academic medical center: a case series. [PDF]

BMC Infect Dis
Burton HJ, Rivere E, Kirk S, Berry H, Lueking R.   +4 more
europepmc   +1 more source

Clinical presentation and effectiveness of antiretroviral therapy in newly diagnosed people living with HIV before, during and after the COVID-19 pandemic. [PDF]

BMJ Public Health
Carbone A, Lombardi F, Tiecco G, Iannone V, Logiudice J, Salvo PF, Scoppettuolo G, Gerami R, Cesanelli F, Salvi M, Cingolani A, Castelli F, Di Giambenedetto S, Torti C, Quiros-Roldan E.   +14 more
europepmc   +1 more source

Effect of rapid antiretroviral therapy initiation on loss to follow-up, virologic failure, and immunologic failure among people living with HIV under the treat-all policy in China: a retrospective cohort study (2016-2023). [PDF]

Front Med (Lausanne)
Ao S, Zheng Y, Yang L, Nie Z, Li P, Long H.   +5 more
europepmc   +1 more source

Neuropsychiatric Tolerability of Long-Acting Cabotegravir and Rilpivirine in People With HIV With Prior INSTI-Related CNS Toxicity: A Real-World Cohort Study. [PDF]

Open Forum Infect Dis
Rosas Cancio-Suárez M, Moreno A, Terrón SDC, Vivancos MJ, Vélez Díaz-Pallarés M, Casado JL, Cano C, Navarro-Soler R, Moreno S, Pérez-Elías MJ.   +9 more
europepmc   +1 more source